Melanoma

**Adjuvant Therapies**

- **Stages 2B, 2C, or 3**
  - IRB#11848: Phase III, Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

- **Stages 3 or 4, resectable**
  - IRB#15661: Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
  - New study coming soon

- **Stages 3 or 4, unresectable**
  - IRB#16125: Phase 1b/2, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients With Metastatic Melanoma
  - IRB#16198: A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

**Non-Mutation Specific**

- IRB#11848: DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Mutation Specific**

- BRAF V600 Mutation
  - New study coming soon

**Uveal Melanoma**

- IRB#16162: A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

**Observational**

- IRB#17104: DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Stages 3 or 4, unresectable**

- IRB#15661: New study coming soon

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

Please refer to Phase I studies for more clinical trial opportunities

http://www.ohsu.edu/research/rda/so/knight.php